Drugs / hMSC-Exos
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04602104 | Nov 2020 → Nov 2022 | acute respiratory distress syndrome | Ruijin Hospital | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hMSC-Exos | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04602104 ↗ |
| Modality | Other / unclassified | “Exosomes are naturally occurring nanosized vesicles and comprised of natural lipid bilayers” NCT04602104 ↗ |
| Route | Inhaled | “7 times aerosol inhalation of hMSC-Exos” NCT04602104 ↗ |